Last reviewed · How we verify
Vecuronium + Atracurium
Vecuronium and atracurium are neuromuscular blocking agents that competitively inhibit acetylcholine at the neuromuscular junction, causing muscle paralysis.
Vecuronium and atracurium are neuromuscular blocking agents that competitively inhibit acetylcholine at the neuromuscular junction, causing muscle paralysis. Used for Muscle relaxation during general anesthesia and mechanical ventilation in surgical procedures, Facilitation of endotracheal intubation.
At a glance
| Generic name | Vecuronium + Atracurium |
|---|---|
| Sponsor | Sir Ganga Ram Hospital |
| Drug class | Neuromuscular blocking agent (non-depolarizing) |
| Target | Nicotinic acetylcholine receptor at the neuromuscular junction |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Both drugs are non-depolarizing neuromuscular blockers that bind to nicotinic acetylcholine receptors at the motor end plate, preventing acetylcholine from binding and triggering muscle contraction. Vecuronium is metabolized hepatically with intermediate duration of action, while atracurium undergoes Hofmann elimination and ester hydrolysis, making it independent of organ function. When used together, they provide combined neuromuscular blockade for surgical anesthesia.
Approved indications
- Muscle relaxation during general anesthesia and mechanical ventilation in surgical procedures
- Facilitation of endotracheal intubation
Common side effects
- Histamine release (atracurium)
- Hypotension
- Tachycardia
- Flushing
- Prolonged neuromuscular blockade
Key clinical trials
- Trial of Therapeutic Hypothermia in Patients With ARDS (PHASE2)
- Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS (PHASE2)
- Evaluation of Atracurium-vecuronium Combination in Laparosocpic Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vecuronium + Atracurium CI brief — competitive landscape report
- Vecuronium + Atracurium updates RSS · CI watch RSS
- Sir Ganga Ram Hospital portfolio CI